Unlocking the Deep Human Genome

We’re saving lives through early detection, better prevention and more effective cures for all disease, starting with cancer.
Media Kit

OverView

Quantgene is building the future of medicine by engineering the most advanced scientific and technological innovations that unlock the Deep Human Genome.

Quantgene combines liquid biopsy, deep genome sequencing and advanced AI to see mutational patterns of disease down to a single molecule. This means diseases like cancer can be detected far earlier than ever before.

Unlocking the Deep Human Genome

We’re saving lives through early detection, better prevention and more effective cures for all disease, starting with cancer.

CONTACT INFORMATION

Santa Monica Headquarters:

2940 Nebraska Ave
Santa Monica, CA 90404
(424) 272-1566

Berlin R&D Unit:

Quantgene Mustererkennungseinheit
Schlüterstr. 39
10629 Berlin, Charlottenburg
Germany

ABOUT QUANTGENE

We are facing a hard truth in healthcare: disease is often treated late in the process, once symptoms have already progressed and prognosis is poor (or have led to a significant decrease in quality of life). At Quantgene, our mission is to use the power of the Deep Human Genome to guide in the early detection and better prevention of disease, starting with cancer. By taking liquid biopsies and combining this with precision sequencing, our advanced machine-learning technology can identify malignant strands of DNA, long before symptoms start to take hold. We strive to save more lives through the early detection and better prevention of disease, starting with cancer.

Quantgene is an advanced medical technology company headquartered in Santa Monica, CA and Berlin, Germany, with clinical sites across Europe and the US. We lead the world in single-molecule precision sequencing utilizing cfDNA and AI-based deep genomics pattern recognition.

Founding

After seeing a number of fundamental issues in current cancer diagnostics, CEO and founder, Jo Bhakdi, was inspired to face theproblem head on. Quantgene started in 2015 in a small UC Berkeley Labunder the leadership of Bhakdi and Dr. Monika Hagen.

Their theory was that most disease can be detected far earlier than it is today by introducing quantitative science and a new level of precision into medical practice. Since then, our expert team of researchers has focused on building the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cfDNA fragments with unprecedented depth and accuracy.

CLINICAL TRIALS

In 2016, Quantgene launched one of the most comprehensive cell-free clinical feasibility trials across leading organizations in the US and Europe, with the goal of collecting 10,000 patient blood samples.

Clinical Trial Protocol: https://clinicaltrials.gov/ct2/show/NCT03517332

Technology:
Quantgene’s GRIFFIN Deep Genomics System

Products

Peace of Mind Across Eight Cancers

Serenity is a preventive care system that offers advanced protection.

Liquid Biopsy cfDNA Platform

DeepGen is a solution to fast-track liquid biopsy research that focuses on deep genomics and AI data exploration

Keypoints

COMPANY MILESTONES

$13MM Raised

Quantgene has raised $13MM in their series A funding round and an open convertible note.

CLIA Certification

Quantgene anticipates CLIA certification on their laboratory process in the next few months.

1st Multi-Cancer Detection Pilot

Quantgene is on track for a scaled launch of its first muti-cancer detection test, Quantgene Serenity™ in 2020.

CLINICAL

cfDNA Trials

Being studied for 15 cancer types in one of the largest cell-free DNA (cfDNA)trials with 10,000 patients across leading oncology centers in the US and Europe.

10,000 Patient Trial

As of 3/19/2020, Quantgene has collected over 5,000 of a 10,000 patient samples for their clinical feasibility study.

Pilot Study for Undiagnosed Population

The company is currently running a pilot study that detects the first cancer in undiagnosed patient populations.

TECHNOLOGY

272 Genes

Sequences thousands of DNA copies across 272 genes and over 70,000 locations including cancer associated targets|.

0.1% MAF

Combines deep sequencing with AI to detect down to 0.1% mutant allele frequency (MAF), which means Serenity can detect a single tumor gene in onethousand non-tumor genes.

Over 6 Billion Genomic Data Points

Generates over 6 billion genomic data points per blood sample to see deeper into a patient’s genomic make-up.

Somatic Mutations vs. Germline Mutations

Goes beyond hereditary risk; it detects cancer mutations occurring in your body currently (somatic mutations vs. germline mutations).

BUILDING LA BIOTECH

Quantgene is committed to solidifying Los Angeles as an innovation hub for healthcare and life sciences.

They host and sponsor monthly meetings for founders of health innovation companies.

They have opened their Santa Monica offices to aspiring health Entrepreneurs as a co-working space.

Building a robust talent pipeline to attract top-notch engineering talent to LA.

LEADERSHIP

Jo Bhakdi

Founder & Chief Executive Officer

Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.

Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.

Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.

Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.

Monika E. Hagen, MD, MBA

Chief Medical Officer

Monika E. Hagen, MD, MBA is the Chief Medical Officer of Quantgene and a board certified General Surgeon, specializing in bariatric surgery. Trained in Germany, Switzerland, and the United States, she has over a decade of experience as a medical doctor, academic surgeon, teacher, medical device expert, and clinical trial specialist. She also received her MBA from the University of Wales in Cardiff, UK.

Dr. Hagen is an international thought leader and lecturer in bariatric and minimally invasive surgery, as well as surgical robotic technology and its clinical applications. She is a frequent speaker at medical conferences and has published extensively on topics ranging from robotic surgery, to clinical trial design to the future of medicine.

Prior to joining Quantgene and utilizing her clinical, strategic planning, and business development expertise, she has served as a regular consultant to financial, technology, medical, and biotech companies. Dr. Hagen divides her time between professional roles in Geneva, Switzerland, Silicon Valley, and Santa Monica, California.

EXPERT TEAM

30 full-time and contract resources across the US and Europe made up of clinicians, technologists, data scientists and business innovators.

CLINICAL ADVISORS

Quantgene is partnering with healthcare and industry experts from world-leading institutions like Stanford, USC, and Berkeley.

Christina Curtis, MD, PhD
Medical Oncology, Stanford University

Cristina Ferrone, MD
GI Surgical Oncologist, Massachusetts General Hospital

Darcy V. Spicer, MD
Medical Oncology, Keck School of Medicine, USC

Linda Rosenstock, MD, MPH
Ethics and Health Policy, Fielding School of Public Health, UCLA

Geroge A. Poultsides, MD, MS
FACS, Surgical Oncology, StanfordUniversity

Eren Berber, MD
Endocrinology and Surgical Oncology, Cleveland Clinic

Press details

AUDIENCE

  • Entrepreneurs
  • Thought Leaders–healthcare, tech
  • Investors at disruptive tech VCs
  • Potential employees in LA and Berlin
  • Clinical partners, biotech and advisors
  • Government officials and influencers
  • Early-adopter, health proactive patients
  • All people with a vested interest in improving healthcare as a system

IN THE NEWS

The Cutting-Edge of AI Cancer Detection

April 30, 2019

Health Transformers: Jo Bhakdi - Quantgene

February 6, 2019

8 A.I. Entrepreneurs to Watch

April 2, 2019

Quantgene CEO, Jo Bhakdi, Recognized by California State Senate for Leadership in Tech

February 28, 2020

Jo Bhakdi of Quantgene, Detect Disease at Early Stages: WeAreLATech Startup Spotlight

February 28, 2020

Defeating Cancer and Unlocking Precision Medicine: Interview with Quantgene Founder Jo Bhakdi

May 5, 2020

MEDIA ASSETS

The Cutting-Edge of AI Cancer Detection

April 30, 2019

Health Transformers: Jo Bhakdi - Quantgene

February 6, 2019

8 A.I. Entrepreneurs to Watch

April 2, 2019

Quantgene CEO, Jo Bhakdi, Recognized by California State Senate for Leadership in Tech

February 28, 2020

Jo Bhakdi of Quantgene, Detect Disease at Early Stages: WeAreLATech Startup Spotlight

February 28, 2020

Defeating Cancer and Unlocking Precision Medicine: Interview with Quantgene Founder Jo Bhakdi

May 5, 2020

MEDIA AND PRESS INQUIRIES

Rachel Strohmeyer
Public Relations
media@quantgene.com